
Hoon J. Chung
Examiner (ID: 296, Phone: (571)272-4059 , Office: P/2474 )
| Most Active Art Unit | 2474 |
| Art Unit(s) | 4173, 2474, 2419, 2416, CQIC |
| Total Applications | 707 |
| Issued Applications | 575 |
| Pending Applications | 11 |
| Abandoned Applications | 123 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18020594
[patent_doc_number] => 20220372093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => TGF-Beta Polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/722328
[patent_app_country] => US
[patent_app_date] => 2022-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722328 | TGF-b polypeptides | Apr 15, 2022 | Issued |
Array
(
[id] => 17913242
[patent_doc_number] => 20220315637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/717740
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717740
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/717740 | Methods of making and using extracellular domain-based chimeric proteins | Apr 10, 2022 | Issued |
Array
(
[id] => 17929805
[patent_doc_number] => 20220324930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/717783
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/717783 | Activatable interleukin 12 polypeptides and methods of use thereof | Apr 10, 2022 | Issued |
Array
(
[id] => 19265393
[patent_doc_number] => 20240209092
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => COMBINATION THERAPIES FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/554870
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554870
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/554870 | COMBINATION THERAPIES FOR TREATING CANCER | Apr 10, 2022 | Pending |
Array
(
[id] => 18013312
[patent_doc_number] => 11505594
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 17/711723
[patent_app_country] => US
[patent_app_date] => 2022-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 67818
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711723
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/711723 | Anti-VEGF protein compositions and methods for producing the same | Mar 31, 2022 | Issued |
Array
(
[id] => 20386595
[patent_doc_number] => 12486312
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => Immunomodulatory proteins with tunable affinities
[patent_app_type] => utility
[patent_app_number] => 17/707511
[patent_app_country] => US
[patent_app_date] => 2022-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 44853
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 218
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707511
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/707511 | Immunomodulatory proteins with tunable affinities | Mar 28, 2022 | Issued |
Array
(
[id] => 19265392
[patent_doc_number] => 20240209091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => METHODS FOR TREATING CANCER USING ANTI-CTLA4 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/553043
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553043
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553043 | METHODS FOR TREATING CANCER USING ANTI-CTLA4 ANTIBODIES | Mar 27, 2022 | Pending |
Array
(
[id] => 19201492
[patent_doc_number] => 20240173391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => THERAPEUTIC COMBINATION FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/552383
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552383
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552383 | THERAPEUTIC COMBINATION FOR TREATING CANCER | Mar 24, 2022 | Pending |
Array
(
[id] => 19248749
[patent_doc_number] => 20240199736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/552113
[patent_app_country] => US
[patent_app_date] => 2022-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32377
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552113
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552113 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Mar 23, 2022 | Pending |
Array
(
[id] => 17720443
[patent_doc_number] => 20220213163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/701108
[patent_app_country] => US
[patent_app_date] => 2022-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701108
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/701108 | IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION | Mar 21, 2022 | Abandoned |
Array
(
[id] => 17720502
[patent_doc_number] => 20220213222
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => PREVENTION AND TREATMENT OF TYPE-1 DIABETES USING AGONISTS OF THE (NA++K+)-ATPASE
[patent_app_type] => utility
[patent_app_number] => 17/701626
[patent_app_country] => US
[patent_app_date] => 2022-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/701626 | Prevention and treatment of type-1 diabetes using agonists of the (NA | Mar 21, 2022 | Issued |
Array
(
[id] => 17895442
[patent_doc_number] => 20220305104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => METHODS OF TREATING ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 17/696028
[patent_app_country] => US
[patent_app_date] => 2022-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/696028 | Methods of treating atopic dermatitis | Mar 15, 2022 | Issued |
Array
(
[id] => 17734720
[patent_doc_number] => 20220220179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => FUSION PROTEIN COMPRISING IL13
[patent_app_type] => utility
[patent_app_number] => 17/693956
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -223
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693956
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/693956 | Fusion protein comprising IL13 | Mar 13, 2022 | Issued |
Array
(
[id] => 20336505
[patent_doc_number] => 20250340625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/556651
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556651
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556651 | ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF | Mar 9, 2022 | Pending |
Array
(
[id] => 17867099
[patent_doc_number] => 20220289834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/691219
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691219
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/691219 | Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody | Mar 9, 2022 | Pending |
Array
(
[id] => 19809518
[patent_doc_number] => 12240889
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-04
[patent_title] => Decoy cytokine receptor
[patent_app_type] => utility
[patent_app_number] => 17/687554
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 75
[patent_no_of_words] => 29462
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687554
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/687554 | Decoy cytokine receptor | Mar 3, 2022 | Issued |
Array
(
[id] => 19491647
[patent_doc_number] => 12110343
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-08
[patent_title] => Anti-plasma kallikrein antibodies
[patent_app_type] => utility
[patent_app_number] => 17/684460
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 5
[patent_no_of_words] => 13930
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684460 | Anti-plasma kallikrein antibodies | Mar 1, 2022 | Issued |
Array
(
[id] => 17672711
[patent_doc_number] => 20220185878
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/684907
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684907
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684907 | Biopharmaceutical compositions | Mar 1, 2022 | Issued |
Array
(
[id] => 17830125
[patent_doc_number] => 20220267429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/684305
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684305
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684305 | Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders | Feb 28, 2022 | Issued |
Array
(
[id] => 19425078
[patent_doc_number] => 12084481
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => HV1 modulators and uses
[patent_app_type] => utility
[patent_app_number] => 17/684346
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 35
[patent_no_of_words] => 21839
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684346 | HV1 modulators and uses | Feb 28, 2022 | Issued |